The Impact of Late Secondary Hyperparathyroidism on Mortality in COVID-19 Patients: A Longitudinal Study

authors:

avatar Sima Hashemipour 1 , avatar Sabereh Afshar 1 , * , avatar Somaieh Kiani 1 , avatar Pouria Shahsavari 1 , avatar Milad Badri 2 , avatar Arf Ghobadi 1 , avatar Seyyed Mohammad Reza Hadizadeh Khairkhahan 1

Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Journal of Inflammatory Diseases: Vol.26, issue 2; 67-78
article type: issue_documents_importer

How To Cite Hashemipour S, Afshar S, Kiani S, Shahsavari P , Badri M , et al. The Impact of Late Secondary Hyperparathyroidism on Mortality in COVID-19 Patients: A Longitudinal Study. J Inflamm Dis. 2022;26(2):e156311. 

Abstract

Background: Adverse effects of high parathormone hormone (PTH) in critical illness have been described in some studies.  Objective: The relationship between high PTH levels with mortality in hospitalized patients with COVID-19 was evaluated in the present study. Methods: A total of 123 patients were included in the study. The patients were evaluated in phase 1 (on admission) and phase 2 (days 4-6 of hospitalization). The patients were categorized into four groups based on the PTH status in both phases: normal PTH1/normal PTH2 (group 1), high PTH1/normal PTH2 (group 2), high PTH1/high PTH2 (group 3), and normal PTH1/high PTH2 (group 4). The multiple logistic regression analysis was performed to examine the independent association of late hyperparathyroidism with mortality. After excluding ineligible participants, 115 patients in phase 1 and 96 patients in phase 2 (days 4-6 of hospitalization) were evaluated. Findings: The level of phase 2 PTH in non-survivors was significantly higher than in survivors (57.5±40.9 pg/mL vs. 27.6±16.2 pg/mL, P=0.001). The mortality rate was significantly higher in high-PTH groups in phase 2 compared to normal-PTH groups in this phase (50% and 42.9% in groups 3 and 4 vs. 6.6% and 18.2% in PTH groups 1 and 2, respectively, P=0.007). Late hyperparathyroidism was associated with 11.4 times higher mortality risk (95% CI: 2.3-56.1, P=0.003). Conclusion: Late hyperparathyroidism remained a significant predictor of mortality after adjusting for the main PTH secretion modulators and disease severity. Late hyperparathyroidism is an independent and strong risk factor for mortality in COVID-19. Further studies are necessary to clarify the mechanisms involved.

References

  • 1.

    A. Kelly and M. A. Levine et al (2013) Hypocalcemia in the critically ill patient. J. Intensive Care Med 28(3), 166-177.

  • 2.

    G. P. Zaloga and B. Chernow et al (1987) The multifactorial basis for hypocalcemia during sepsis: studies of the parathyroid hormone-vitamin D axis. Ann Intern Med 107(1), 36-41.

  • 3.

    J. Liu, P. Han, J. Wu, J. Gong et al (2020) Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health 13(9), 1224-1228.

  • 4.

    S. Bennouar, A.B. Cherif, A. Kessira et al (2021) Vitamin D deficiency and low serum calcium as predictors of poor prognosis in patients with severe COVID-19. J Am Coll Nutr 40(2), 104-110.

  • 5.

    S Hashemipour, S Kiani, P Shahsavari et al (2022) Hypocalcemia in hospitalized patients with COVID-19: roles of hypovitaminosis D and functional hypoparathyroidism. J Bone Miner Metab: 1-7. doi.org/10.1007/s00774-022-01330-w.

  • 6.

    LD Filippo, AM Formenti, P Rovere-Querini et al (2020) Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68(3), 475-478.

  • 7.

    J W Martha, A Wibowo, R Pranata et al (2021) Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev 15(337-342). doi.org/10.1016/j.dsx.2021.01.003.

  • 8.

    J Sun, W Zhang, LZou et al (2020) Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY) 6;12(12) (2020), 11287.

  • 9.

    S Bennouar, A B Cherif, A Kessira et al (2021) Vitamin D deficiency and low serum calcium as predictors of poor prognosis in patients with severe COVID-19. J Am Coll Nutr 40(2), 104-110.##.

  • 10.

    Murthi, M., et al et al (2021) Association of hypocalcemia with in-hospital mortality and complications in patients with acute pulmonary embolism: results from the 2017 Nationwide Inpatient Sample. BMC Pulm Med 21(1), 1-6.##.

  • 11.

    T Steele, R Kolamunnage-Dona, C Downey et al (2013) Assessment and clinical course of hypocalcemia in critical illness. Critical Care 17(3), 1-10.

  • 12.

    B Torres, P Alcubilla, A Gonzlez-Cordn et al (2021) Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. Int J Infect Dis 104, 164-168.##.

  • 13.

    W T Davis, P C Ng, K L Medellin et al (2022). Association of Hypocalcemia With Mortality of Combat Casualties With Brain Injury and Polytrauma Transported by Critical Care Air Transport Teams. Mil Med, doi.org/10.1093/milmed/usac029.##.

  • 14.

    F Carlstedt, L Lind, J Rastad et al (2018). Association of admission serum levels of vitamin D, calcium, Phosphate, magnesium and parathormone with clinical outcomes in neurosurgical ICU patients. Sci Rep 8(1), 1-8.##.

  • 15.

    J Hu, Z Luo, X Zhao et al (2013). Changes in the calcium-parathyroid hormone-vitamin d axis and prognosis for critically ill patients: a prospective observational study." PloS one 8(9), e75441.

  • 16.

    SH Ardehali, S Dehghan, AR Baghestani et al (2018) Association of admission serum levels of vitamin D, calcium, Phosphate, magnesium and parathormone with clinical outcomes in neurosurgical ICU patients. Sci Rep 8(1), 1-8.

  • 17.

    S. Hashemipour, S. Kiani, P. Shahsavari et al (2022) Contributing factors for calcium changes during hospitalization in COVID-19: A Longitudinal Study. Int J Endocrinol Metab 20(2). 10.5812/ijem-122378.

  • 18.

    D Goltzman, CJ Rosen, JE Mulder et al (2020). Diagnostic approach to hypocalcemia. Up To Date, Sep;69(3):485-95.

  • 19.

    J Chris Gallagher, A J Sai et al (2010) Vitamin D insufficiency, deficiency, and bone health, Oxford University Press. J Clin Endocrinol Metab 95, 2630-2633. https://doi.org/10.1210/jc.2010-0918.

  • 20.

    E Alemzadeh, E Alemzadeh, M Ziaee et al (2021). The effect of low serum calcium level on the severity and mortality of Covid patients: A systematic review and metaanalysis. Immun Inflamm Dis 9(4), 1219-1228.

  • 21.

    P Nair, P Lee, C Reynolds et al (2013)Significant perturbation of vitamin Dparathyroidcalcium axis and adverse clinical outcomes in critically ill patients. Intensive Care Med 39(2), 267-274.

  • 22.

    R Baczynski, R Kohan, M Magott et al (1985) Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27(5), 718-725.

  • 23.

    KD Schlter, HM Piper et al (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37(1), 34-41.

  • 24.

    Rostand, S. G. and T. B. Dreke (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56(2), 383-392.

  • 25.

    Smogorzewski, M et al (1995) PTH, chronic renal failure and myocardium. Miner Electrolyte Metab 21(1-3), 55-62.

  • 26.

    SJ Brown, MD Ruppe, LS Tabatabai et al (2017) The parathyroid gland and heart disease. Methodist Debakey Cardiovasc 13(2), 49.

  • 27.

    Y Jiang, A Yoshida, C Ishioka et al (1992) Parathyroid hormone inhibits immunoglobulin production without affecting cell growth in human B cells. Clin Immunol 65(3), 286-293.

  • 28.

    Massry, S. G. and M. Smogorzewski (2001) Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone Kidney Int 59, S195-S196.

  • 29.

    AS Geara, MR Castellanos, C Bassil et al (2010) Effects of parathyroid hormone on immune function. Clin Dev Immunol. 10.1155/2010/418695.

  • 30.

    JM Alexiewicz, M Smogorzewski, M Klin et al (1995) Effect of treatment of hemodialysis patients with nifedipine on metabolism and function of polymorphonuclear leukocytes. Am J Kidney Dis 25(3), 440-444.

  • 31.

    WH Hrl, M Haag-Weber, B Mai et al (1995) Verapamil reverses abnormal [Ca2+] i and carbohydrate metabolism of PMNL of dialysis patients. Kidney Int 47(6), 1741-1745.

  • 32.

    JM Alexiewicz, M Smogorzewski, M Akmal et al (1997) A longitudinal study on the effect of nifedipine therapy and its discontinuation on [Ca2+] i and proliferation of B lymphocytes of dialysis patients. Am J Kidney Dis 29(2), 233-238.

  • 33.

    JM Alexiewicz, M Smogorzewski, SK Gill et al (1997) Time course of the effect of nifedipine therapy and its discontinuation on [Ca2+] i and phagocytosis of polymorphonuclear leukocytes from hemodialysis patients. Am J Nephrol 17(1), 12-16.##.